A Progressive Mouse Model of Parkinson's Disease: The Thy1-aSyn ("Line 61") Mice

Neurotherapeutics

Volumn 9, Issue 2, 2012, Pages 297-314

  Chesselet, Marie Francoise ^a   Richter, Franziska ^a   Zhu, Chunni ^a   Magen, Iddo ^a   Watson, Melanie B ^a   Subramaniam, Sudhakar R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Alpha synuclein; Mouse model; Parkinson's disease; Progressive; Thy1 aSyn

Indexed keywords

ALPHA SYNUCLEIN; MESSENGER RNA; PROTEINASE K; THY 1 ANTIGEN;

ANXIETY; CELL LOSS; COGNITIVE DEFECT; COLON MOTILITY; CORPUS STRIATUM; DISEASE COURSE; DOPAMINE RELEASE; DOPAMINERGIC NERVE CELL; GENE INSERTION; HUMAN; IMMUNOHISTOCHEMISTRY; MOTOR DYSFUNCTION; NEUROPROTECTION; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; OLFACTORY NERVE DISEASE; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SUBSTANTIA NIGRA; THALAMUS; TRANSGENE; X CHROMOSOME;

ALPHA-SYNUCLEIN; ANIMALS; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; HUMANS; MICE; MICE, NEUROLOGIC MUTANTS; PARKINSON DISEASE; PROMOTER REGIONS, GENETIC;

EID: 84859712842     PISSN: 19337213     EISSN: 18787479     Source Type: Journal    
DOI: 10.1007/s13311-012-0104-2     Document Type: Review

References (91)

1. Meissner WG, Frasier M, Gasser T, et al. Priorities in Parkinson's disease research. Nat Rev Drug Discov 2011; 10: 377-393.
2. DeLong MR, Juncos JL. Parkinson's disease and other extrapyramidal movement disorders. In: Harrison's Principles of Internal Medicine. Fauci, AS McGraw-Hill Medical, New York, 2008: 2549-2559.
3. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 2003; 24: 197-211.
4. Delfs JM, Ciaramitaro VM, Soghomonian JJ, Chesselet MF. Unilateral nigrostriatal lesions induce a bilateral increase in glutamate decarboxylase messenger RNA in the reticular thalamic nucleus. Neuroscience 1996; 71: 383-395.
5. Chaudhuri KR, Odin P. The challenge of non-motor symptoms in Parkinson's disease. Prog Brain Res 2010; 184: 325-341.
6. Olanow CW, Stern MB, Sethi K. The scientific and clinical basis for the treatment of Parkinson disease. Neurology 2009; 72: S1-136.
7. Lohle M, Reichmann H. Clinical neuroprotection in Parkinson's disease - still waiting for the breakthrough. J Neurol Sci 2010; 289: 104-114.
8. Langston JW. Epidemiology versus genetics in Parkinson's disease: progress in resolving an age-old debate. Ann Neurol 1998; 44: S45-52.
9. Bronstein J, Carvey P, Chen H, et al. Meeting report: consensus statement-Parkinson's disease and the environment: collaborative on health and the environment and Parkinson's Action Network (CHE PAN) conference June 26-28, 2007. Environ Health Perspect 2009; 117: 117-121.
10. Hamza TH, Chen H, Hill-Burns EM, et al. Genome-wide gene-environment study identifies glutamate receptor gene GRIN2A as a Parkinson's disease modifier gene via interaction with coffee. PLoS Genet 2011; 7: e1002237.
11. Manthripragada AD, Costello S, Cockburn MG, Bronstein JM, Ritz B. Paraoxonase 1, agricultural organophosphate exposure, and Parkinson disease. Epidemiology 2010; 21: 87-94.
12. Burbulla LF, Krebiehl G, Kruger R. Balance is the challenge - the impact of mitochondrial dynamics in Parkinson's disease. Eur J Clin Invest 2010; 40: 1048-1060.
13. Spillantini MG, Goedert M. The alpha-synucleinopathies: Parkinson's disease, dementia with Lewy bodies, and multiple system atrophy. Ann N Y Acad Sci 2000; 920: 16-27.
14. Edwards TL, Scott WK, Almonte C, et al. Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease. Ann Hum Genet 2010; 74: 97-109.
15. Gatto NM, Rhodes SL, Manthripragada AD, et al. alpha-Synuclein gene may interact with environmental factors in increasing risk of Parkinson's disease. Neuroepidemiology 2010; 35: 191-195.
16. Huang Y, Rowe DB, Halliday GM. Interaction between alpha-synuclein and tau genotypes and the progression of Parkinson's disease. J Parkinson's Dis 2011; 1: 271-276.
17. Magen I, Chesselet MF. Genetic mouse models of Parkinson's disease: the state of the art. Prog Brain Res 2010; 184: 53-87.
18. Chesselet MF, Richter F. Modelling of Parkinson's disease in mice. Lancet Neurol 2011; 10: 1108-1118.
19. Dawson TM, Ko HS, Dawson VL. Genetic animal models of Parkinson's disease. Neuron 2010; 66: 646-661.
20. Harvey BK, Richie CT, Hoffer BJ, Airavaara M. Transgenic animal models of neurodegeneration based on human genetic studies. J Neural Transm 2011; 118: 27-45.
21. Rockenstein E, Mallory M, Hashimoto M, et al. Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters. J Neurosci Res 2002; 68: 568-578.
22. Masliah E, Rockenstein E, Veinbergs I, et al. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 2000; 287: 1265-1269.
23. Hashimoto M, Rockenstein E, Masliah E. Transgenic models of alpha-synuclein pathology: past, present, and future. Ann N Y Acad Sci 2003; 991: 171-188.
24. Lam HA, Wu N, Cely I, et al. Elevated tonic extracellular dopamine concentration and altered dopamine modulation of synaptic activity precede dopamine loss in the striatum of mice overexpressing human alpha-synuclein. J Neurosci Res 2011; 89: 1091-1102.
25. van der Putten H, Wiederhold KH, Probst A, et al. Neuropathology in mice expressing human alpha-synuclein. J Neurosci 2000; 20: 6021-6029.
26. Fleming SM, Salcedo J, Fernagut PO, et al. Early and progressive sensorimotor anomalies in mice overexpressing wild-type human alpha-synuclein. J Neurosci 2004; 24: 9434-9440.
27. Lim Y, Kehm VM, Lee EB, et al. alpha-Syn suppression reverses synaptic and memory defects in a mouse model of dementia with Lewy bodies. J Neurosci 2011; 31: 10076-10087.
28. Spillantini MG, Schmidt ML, Lee VM, Trojanowski JQ, Jakes R, Goedert M. Alpha-synuclein in Lewy bodies. Nature 1997; 388: 839-840.
29. Fernagut PO, Hutson CB, Fleming SM, et al. Behavioral and histopathological consequences of paraquat intoxication in mice: effects of alpha-synuclein over-expression. Synapse 2007; 61: 991-1001.
30. Neumann M, Muller V, Kretzschmar HA, Haass C, Kahle PJ. Regional distribution of proteinase K-resistant alpha-synuclein correlates with Lewy body disease stage. J Neuropathol Exp Neurol 2004; 63: 1225-1235.
31. Halliday GM, Holton JL, Revesz T, Dickson DW. Neuropathology underlying clinical variability in patients with synucleinopathies. Acta Neuropathol 2011; 122(2): 187-204.
32. Braak H, de Vos RA, Bohl J, Del Tredici K. Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci Lett 2006; 396: 67-72.
33. Hawkes CH, Del Tredici K, Braak H. Parkinson's disease: a dual-hit hypothesis. Neuropathol Appl Neurobiol 2007; 33: 599-614.
34. Beal MF. Parkinson's disease: a model dilemma. Nature 2010; 466: S8-S10.
35. Cheng HC, Ulane CM, Burke RE. Clinical progression in Parkinson disease and the neurobiology of axons. Ann Neurol 2010; 67: 715-725.
36. Richfield EK, Thiruchelvam MJ, Cory-Slechta DA, et al. Behavioral and neurochemical effects of wild-type and mutated human alpha-synuclein in transgenic mice. Exp Neurol 2002; 175: 35-48.
37. Wakamatsu M, Ishii A, Iwata S, et al. Selective loss of nigral dopamine neurons induced by overexpression of truncated human alpha-synuclein in mice. Neurobiol Aging 2008; 29: 574-585.
38. Shin JH, Ko HS, Kang H, et al. PARIS (ZNF746) repression of PGC-1alpha contributes to neurodegeneration in Parkinson's disease. Cell 2011; 144: 689-702.
39. Sulzer D. Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease. Trends Neurosci 2007; 30: 244-250.
40. Manning-Bog AB, McCormack AL, Purisai MG, Bolin LM, Di Monte DA. Alpha-synuclein overexpression protects against paraquat-induced neurodegeneration. J Neurosci 2003; 23: 3095-3099.
41. Hean S, Richter F, Torres ES, et al. Mice overexpressing human alpha synuclein (Thy1-aSyn) show dopamine loss, catalepsy and severe motor deficits partially rescued by L-DOPA at 14 months of age. Neurosci Abstr 2010; 750. 27/H20:.
42. Sossi V, de la Fuente-Fernandez R, Nandhagopal R, et al. Dopamine turnover increases in asymptomatic LRRK2 mutations carriers. Mov Disord 2010; 25: 2717-2723.
43. Chesselet MF. Dopamine and Parkinson's disease: is the killer in the house? Mol Psychiatry 2003; 8: 369-370.
44. Hattoria N, Wanga M, Taka H, et al. Toxic effects of dopamine metabolism in Parkinson's disease. Parkinsonism Relat Disord 2009; 15(suppl 1): S35-S38.
45. Lawal HO, Chang HY, Terrell AN, et al. The Drosophila vesicular monoamine transporter reduces pesticide-induced loss of dopaminergic neurons. Neurobiol Dis 2010; 40: 102-112.
46. Ritz BR, Manthripragada AD, Costello S, et al. Dopamine transporter genetic variants and pesticides in Parkinson's disease. Environ Health Perspect 2009; 117: 964-969.
47. Caudle WM, Richardson JR, Wang MZ, et al. Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration. J Neurosci 2007; 27: 8138-8148.
48. McDowell K, Chesselet MF. Animal models of the non-motor features of Parkinson's disease. Neurobiol Dis 2012;(in press).
49. Lang AE, Obeso JA. Time to move beyond nigrostriatal dopamine deficiency in Parkinson's disease. Ann Neurol 2004; 55: 761-765.
50. Ross GW, Petrovitch H, Abbott RD, et al. Association of olfactory dysfunction with risk for future Parkinson's disease. Ann Neurol 2008; 63: 167-173.
51. Fleming SM, Tetreault NA, Mulligan CK, Hutson CB, Masliah E, Chesselet MF. Olfactory deficits in mice overexpressing human wildtype alpha-synuclein. Eur J Neurosci 2008; 28: 247-256.
52. Marxreiter F, Nuber S, Kandasamy M, et al. Changes in adult olfactory bulb neurogenesis in mice expressing the A30P mutant form of alpha-synuclein. Eur J Neurosci 2009; 29: 879-890.
53. Wang L, Fleming SM, Chesselet MF, Tache Y. Abnormal colonic motility in mice overexpressing human wild-type alpha-synuclein. Neuroreport 2008; 19: 873-876.
54. Abbott RD, Petrovitch H, White LR, et al. Frequency of bowel movements and the future risk of Parkinson's disease. Neurology 2001; 57: 456-462.
55. Savica R, Carlin JM, Grossardt BR, et al. Medical records documentation of constipation preceding Parkinson disease: a case-control study. Neurology 2009; 73: 1752-1758.
56. Kuo YM, Li Z, Jiao Y, et al. Extensive enteric nervous system abnormalities in mice transgenic for artificial chromosomes containing Parkinson disease-associated alpha-synuclein gene mutations precede central nervous system changes. Hum Mol Genet 2010; 19: 1633-1650.
57. Abbott RD, Ross GW, White LR, et al. Excessive daytime sleepiness and subsequent development of Parkinson disease. Neurology 2005; 65: 1442-1446.
58. Kudo T, Loh DH, Truong D, Wu Y, Colwell CS. Circadian dysfunction in a mouse model of Parkinson's disease. Exp Neurol 2011; 232(1): 66-75.
59. Janvin CC, Aarsland D, Larsen JP. Cognitive predictors of dementia in Parkinson's disease: a community-based, 4-year longitudinal study. J Geriatr Psychiatry Neurol 2005; 18: 149-154.
60. Magen I, Fleming S, Garcia E, et al. Cognitive deficits in a mouse model of pre-manifest Parkinson's disease. Eur J Neurosci 2011 (in press).
61. Mochizuki-Kawai H, Mochizuki S, Kawamura M. A flexible sequential learning deficit in patients with Parkinson's disease: a 2 x 8 button-press task. Exp Brain Res 2010; 202: 147-153.
62. Magen I, Chesselet MF. Mouse Models of Cognitive Deficits Due to Alpha-Synuclein Pathology. J Parkinsons Dis 2011; 1: 217-227.
63. Torres ES, Zelikowsky M, Richter F, et al. Mice overexpressing human alpha synuclein under the Thy1-promotor show increased fear conditioning and altered responses in anxiety related behavior. Neurosci Abstr 2010; 750. 25/H18.
64. Mulligan CK, Fleming SM, Dorriz P, Masliah E, Chesselet MF. Mice overexpressing human wildtype alpha-synuclein under the Thy-1 promoter exhibit anomalies in behavioral tests of anxiety. Neurosci Abstr 2008; 742. 19/U28.
65. Mirelman A, Gurevich T, Giladi N, Bar-Shira A, Orr-Urtreger A, Hausdorff JM. Gait alterations in healthy carriers of the LRRK2 G2019S mutation. Ann Neurol 2011; 69: 193-197.
66. Fleming SM, Salcedo J, Hutson CB, et al. Behavioral effects of dopaminergic agonists in transgenic mice overexpressing human wildtype alpha-synuclein. Neuroscience 2006; 142: 1245-1253.
67. Fredriksson A, Plaznik A, Sundstrom E, Jonsson G, Archer T. MPTP-induced hypoactivity in mice: reversal by L-dopa. Pharmacol Toxicol 1990; 67: 295-301.
68. Oksman M, Tanila H, Yavich L. Behavioural and neurochemical response of alpha-synuclein A30P transgenic mice to the effects of L-DOPA. Neuropharmacology 2009; 56: 647-652.
69. Cools R. Dopaminergic modulation of cognitive function-implications for L-DOPA treatment in Parkinson's disease. Neurosci Biobehav Rev 2006; 30: 1-23.
70. Rommelfanger KS, Edwards GL, Freeman KG, Liles LC, Miller GW, Weinshenker D. Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice. Proc Natl Acad Sci U S A 2007; 104: 13804-13809.
71. Wu N, Joshi PR, Cepeda C, Masliah E, Levine MS. Alpha-synuclein overexpression in mice alters synaptic communication in the corticostriatal pathway. J Neurosci Res 2010; 88: 1764-1776.
72. Watson JB, Hatami A, David H, et al. Alterations in corticostriatal synaptic plasticity in mice overexpressing human alpha-synuclein. Neuroscience 2009; 159: 501-513.
73. McGeer PL, Itagaki S, Akiyama H, McGeer EG. Rate of cell death in parkinsonism indicates active neuropathological process. Ann Neurol 1988; 24: 574-576.
74. Mogi M, Nagatsu T. Neurotrophins and cytokines in Parkinson's disease. Adv Neurol 1999; 80: 135-139.
75. Ouchi Y, Yagi S, Yokokura M, Sakamoto M. Neuroinflammation in the living brain of Parkinson's disease. Parkinsonism Relat Disord 2009;(15 suppl 3): S200-S204.
76. Watson MB, Lee SK, Richter F, Masliah E, Chesselet MF. Regionally specific microglial activation precedes neuropathology and peripheral immune response in mice over-expressing wildtype alpha synuclein. Neurosci Abstr 2011; 357. 12/AA31.
77. Bas J, Calopa M, Mestre M, et al. Lymphocyte populations in Parkinson's disease and in rat models of parkinsonism. J Neuroimmunol 2001; 113: 146-152.
78. Baba Y, Kuroiwa A, Uitti RJ, Wszolek ZK, Yamada T. Alterations of T-lymphocyte populations in Parkinson disease. Parkinsonism Relat Disord 2005; 11: 493-498.
79. Brochard V, Combadiere B, Prigent A, et al. Infiltration of CD4+ lymphocytes into the brain contributes to neurodegeneration in a mouse model of Parkinson disease. J Clin Invest 2009; 119: 182-192.
80. McGeer PL, Itagaki S, Boyes BE, McGeer EG. Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988; 38: 1285-1291.
81. Song DD, Shults CW, Sisk A, Rockenstein E, Masliah E. Enhanced substantia nigra mitochondrial pathology in human alpha-synuclein transgenic mice after treatment with MPTP. Exp Neurol 2004; 186: 158-172.
82. Richter F, Gao F, Bove N, et al. Transcriptome network and pathway analyses reveal early alterations in dopaminergic neurons of mice overexpressing human wild-type alpha-synuclein (Thy1-aSyn). Neurosci Abstr 2011; 357. 07/AA26.
83. Langfelder P, Horvath S. WGCNA: an R package for weighted correlation network analysis. BMC Bioinformatics 2008; 9: 559.
84. Fleming SM, Mulligan CK, Richter F, et al. A pilot trial of the microtubule-interacting peptide (NAP) in mice overexpressing alpha-synuclein shows improvement in motor function and reduction of alpha-synuclein inclusions. Mol Cell Neurosci 2011; 46: 597-606.
85. Lee KW, Chen W, Junn E, et al. Enhanced phosphatase activity attenuates alpha-Synucleinopathy in a mouse model. J Neurosci 2011; 31: 6963-6971.
86. Koob AO, Ubhi K, Paulsson JF, et al. Lovastatin ameliorates alpha-synuclein accumulation and oxidation in transgenic mouse models of alpha-synucleinopathies. Exp Neurol 2010; 221: 267-274.
87. Bordet T, Buisson B, Michaud M, et al. Identification and characterization of cholest-4-en-3-one, oxime (TRO19622), a novel drug candidate for amyotrophic lateral sclerosis. J Pharmacol Exp Ther 2007; 322: 709-720.
88. Bordet T, Pruss RM. Targeting neuroprotection as an alternative approach to preventing and treating neuropathic pain. Neurotherapeutics 2009; 6: 648-662.
89. Schaller S, Paradis S, Ngoh GA, et al. TRO40303, a new cardioprotective compound, inhibits mitochondrial permeability transition. J Pharmacol Exp Ther 2010; 333: 696-706.
90. Richter F, Fleming SM, Michaud M, et al. The cholesterol-oximes TRO19622 and TRO40303 affect motor function, olfaction, and alpha synuclein aggregation in mice overexpressing human alpha synuclein under the Thy1 promoter. Neurosci Abstr 2010; 750. 28/H21.
91. Lemesre V, Richter F, Fleming SM, et al. The glucocerebrosidase pharmacological chaperone afegostat-tartrate (AT2101) partially improves motor and olfactory function and alters the size of alpha-synuclein inclusions in mice overexpressing alpha-synuclein. Neurosci Abstr 2010; 750. 29/H22.